Free Trial

Metsera logo with Medical background

Key Points

  • Metsera has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, marking a significant shift in analyst sentiment.
  • Despite this downgrade, several brokerages maintain a "buy" rating for Metsera, with an average target price set at $59.00.
  • The company recently reported an earnings per share (EPS) loss of ($0.66) for the last quarter, which may impact investor confidence.
  • MarketBeat previews top five stocks to own in October.
Like this article? Share it with a colleague.